Alnylam's RNAi drug vutrisiran cuts mortality in ATTR-CM by 33% - FDA submission planned
Alnylam’s experimental drug vutrisiran has shown promise for the treatment of transthyretin amyloidosis (ATTR) in a phase 3 clinical trial.
Archives for June 25, 2024
Novo Nordisk's Mim8 significantly reduces bleeds in hemophilia A - plans approval submission
Once monthly treatment with Novo Nordisk’s antibody treatment reduced annual treated bleeds to zero in 95% previously untreated people with hemophilia A.
PolTREG’s regulatory T cell therapy shows promise in type-1 diabetes
Results from a phase 1/2 clinical trial revealed that PolTREG’s regulatory T cell (Treg) therapy, PTG-007, was able to restore insulin secretion in children with type-1 diabetes.
Inside the FDA's Accelerated Approval: How it’s extending lives and improving patient care
Last week, OSP had the pleasure of speaking with Ginny Beakes-Read at the DIA Global conference.
Novo Nordisk announces $4.1BN investment to expand US manufacturing capacity
Yesterday (June 24) Novo Nordisk unveiled plans to invest $4.1 billion (approximately €3.8 billion) in a new manufacturing facility in Clayton, North Carolina.